MARKET

XLO

XLO

Xilio Therapeutics, Inc.
NASDAQ
8.36
-0.45
-5.11%
After Hours: 8.36 0 0.00% 16:10 05/15 EDT
OPEN
8.80
PREV CLOSE
8.81
HIGH
8.81
LOW
8.34
VOLUME
36.92K
TURNOVER
--
52 WEEK HIGH
16.52
52 WEEK LOW
6.47
MARKET CAP
50.02M
P/E (TTM)
-1.9946
1D
5D
1M
3M
1Y
5Y
1D
Xilio Therapeutics reports Q1 results
Seeking Alpha · 3d ago
Xilio Therapeutics files $250M mixed securities shelf
TipRanks · 3d ago
XILIO THERAPEUTICS INC - MAY OFFER UP TO $17.22 MLN COMMON STOCK UNDER SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING
Reuters · 3d ago
XILIO THERAPEUTICS INC - MAY OFFER UP TO $250 MLN IN SECURITIES - SEC FILING
Reuters · 3d ago
*Xilio Therapeutics: Cash Runway Into Early 2028 >XLO
Dow Jones · 3d ago
XILIO THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES PIPELINE AND BUSINESS UPDATES
Reuters · 3d ago
Press Release: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Dow Jones · 3d ago
Weekly Report: what happened at XLO last week (0504-0508)?
Weekly Report · 4d ago
More
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain.

Webull offers Xilio Therapeutics Inc stock information, including NASDAQ: XLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XLO stock methods without spending real money on the virtual paper trading platform.